Broadcast Date: September 30, 2022
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
The potential of gene modifying as a therapeutic has come to fruition prior to now a number of years, as medical information from numerous research has proven very optimistic outcomes. Merging that potential with novel mRNA applied sciences—which have additionally demonstrated their worth and flexibility throughout the COVID-19 pandemic—might present scientists and clinicians with an unmatched weapon within the arsenal to combat numerous ailments. Specifically, Cas13 has been used to focus on RNA viruses in cell tradition, however solely not too long ago has efficacy in animal fashions been demonstrated.
That is the third webinar in a sequence of 4, cohosted by GEN and The CRISPR Journal, that’s diving deep into the burgeoning world of mRNA analysis and therapeutics. Our distinguished visitor for this occasion, Dr. Philip Santangelo, will introduce necessary points of the right way to use mRNA to specific Cas13 and use it as an antiviral agent. Moreover, Dr. Santangelo will focus on information design, screening, the significance of controls, and the right way to apply this strategy in vivo towards a number of pathogens.
A dwell Q&A session adopted the presentation, providing an opportunity to pose inquiries to our skilled panelist.
